FOXA1 expression was significantly associated with shorter relapse-free survival in patients of advanced stage who received bevacizumab treatment combined with EGFR-TKIs, but not associated with relapse-free survival in LUAD patients of advanced stage who received EGFR-TKI treatment alone (Fig. 8D), implying that overexpression of FOXA1 probably contributes to tumor cells survival during anti-angiogenesis therapy. This evidence concerns the gene EGFR and neoplasm.